Lixisenatide reduces glycaemic variability in insulin-treated patients with type 2 diabetes

"Chronic hyperglycaemia and glucose variability are associated with the development of chronic diabetes-related complications. We conducted a pooled analysis of patient-level data from three 24-week, randomized, phase III clinical trials to evaluate the impact of lixisenatide (LIXI) on glycaemi...

Descripción completa

Detalles Bibliográficos
Autores Principales: Umpierrez G.E., O'Neal D., DiGenio A., Goldenberg R., Hernandez-Triana E., Lin J., Park C.-Y., Renard E., Kovatchev B.
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: Blackwell Publishing Ltd 2017
Materias:
Acceso en línea:https://repository.urosario.edu.co/handle/10336/23850
https://doi.org/10.1111/dom.12930